Bosentan Effects in Inoperable Forms of Chronic Thromboembolic Pulmonary Hypertension
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
The present trial investigates a possible use of oral bosentan, which is currently approved
for the treatment of symptoms of pulmonary arterial hypertension (PAH), to patients suffering
from inoperable chronic thromboembolic pulmonary hypertension (CTEPH) because of (i)
peripheral localization of thrombotic material or (ii) persistent or recurrent pulmonary
hypertension after pulmonary endarterectomy.